Key result
Rivaroxaban is linked to severe, hypotensive vaginal bleeding in a young woman.
Why the study?
Novel Oral Anticoagulants like rivaroxaban have significant but rare severe bleeding side effects in women that require further characterization.
Does rivaroxaban cause severe vaginal bleeding in women treated for pulmonary thrombosis prevention?
Case Report (n=1)
No
Does rivaroxaban cause severe vaginal bleeding in women treated for pulmonary thrombosis prevention?
Rivaroxaban can cause severe vaginal bleeding (menorrhagia) in women, highlighting the need for awareness of this rare but dangerous adverse effect.
May signal rare vaginal bleeding risk with rivaroxaban in women; case report leaves open need for incidence data.
Background: The Novel Oral Anticoagulants (NOACs), despite numerous benefits, such as the ease of use and less drug involvement, provide extensive adverse effects. One of the most significant, but rare side effects of them in women is severe and dangerous bleeding. Case presentation: In this study, we reported a case of severe vaginal bleeding (manometric hemorrhage) in a woman receiving rivaroxaban to prevent pulmonary thrombosis. Conclusion: The oral anticoagulant rivaroxaban could present a rare adverse effect on women.
No takes yet. Share an insight, caveat, or question.
Feizi et al. (2020) conducted a case report in Deep venous thrombosis and pulmonary embolism (n=1). Rivaroxaban was evaluated on Severe vaginal bleeding. Rivaroxaban administration was associated with severe vaginal bleeding and hypotension in a 41-year-old woman two months after initiating treatment for recurrent thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: